ストックスクリーナーアプリを入手
5.78
1.37%
-0.08
アフターアワーズ：
5.78
Aclaris Therapeutics Inc (ACRS) 最新ニュース
Sei Investments Co. Makes New Investment in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Dimensional Fund Advisors LP Has $1.91 Million Stock Position in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
FDA Fast Track Status Advances Aclaris Lichen Planus Drug - mychesco.com
HC Wainwright Has Pessimistic Outlook of ACRS Q3 Earnings - MarketBeat
Renaissance Technologies LLC Has $1.89 Million Stake in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Aclaris Therapeutics, Inc. (ACRS) stock price, news, quote and history - Yahoo Finance Australia
Aclaris Raises Capital as Drug Pipeline Spending Accelerates - MyChesCo
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Brokerages - MarketBeat
Aclaris Therapeutics, Inc. (ACRS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade - Zacks Investment Research
Weekly Recap: Q2 loss, runway into 2028 and Fast Track for modzatinib - TradingView
Aclaris Therapeutics (ACRS) Stock Drifts Lower As Losses Deepen On Thin Revenue - simplywall.st
Aclaris Updates At-The-Market Equity Sales Agreement - The Globe and Mail
Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Down 6%Here's What Happened - MarketBeat
US FDA Fast-tracks Aclaris’ Modzatinib for Lichen Planus - The Dermatology Digest
FDA grants fast track status to Aclaris’ lichen planus drug By Investing.com - Investing.com Nigeria
Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Aclaris Therapeutics Inc (8AT.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Aclaris Therapeutics (NASDAQ:ACRS) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Aclaris Therapeutics (ACRS) Releases Q2 2026 Earnings: Revenue Declines, Losses Narrow - Quiver Quantitative
FDA grants fast track status to Aclaris’ lichen planus drug - Investing.com
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) - Yahoo Finance
Aclaris Therapeutics (NASDAQ: ACRS) widens loss as R&D spending accelerates - Stock Titan
Form 8K Aclaris Therapeutics Inc For: 6 August By Investing.com - Investing.com South Africa
Aclaris Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates - finance.yahoo.com
Earnings Flash (ACRS) Aclaris Therapeutics, Inc. Reports Q2 Revenue $1.6M, vs. FactSet Est of $1.4M - marketscreener.com
Earnings Flash (ACRS) Aclaris Therapeutics Posts Q2 Net Loss $0.15 a Share, vs. FactSet Est of $0.16 Loss - marketscreener.com
Aclaris Therapeutics reports Q2 2026 net loss of $21.5M, cash runway through 2028 - TradingView
ACRS: Higher net loss and R&D spend offset by strong cash reserves and major clinical milestones ahead - TradingView
Aclaris Therapeutics Inc earnings beat by $0.01, revenue topped estimates - Investing.com
Aclaris Therapeutics Q2 revenue beats analyst estimates - TradingView
BRIEF-Aclaris Therapeutics Q2 Net Income USD -21.505 Million Vs. IBES Estimate USD -21.3 Million - TradingView
Aclaris Therapeutics 2Q Loss/Shr 15c >ACRS - Moomoo
Aclaris Therapeutics (NASDAQ: ACRS) CSO gets shares, some withheld - Stock Titan
Aclaris Therapeutics (NASDAQ:ACRS) Sets New 1-Year HighStill a Buy? - MarketBeat
Aclaris Therapeutics Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Aclaris Therapeutics (ACRS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Aclaris Therapeutics Inc (ACRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aclaris Therapeutics Inc (ACRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aclaris Therapeutics Inc (ACRS) Cash Flow - TradingKey
Kalehua Capital Management LLC Makes New $6.87 Million Investment in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Aclaris Therapeutics Inc (ACRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ACRS|Aclaris Therapeutics Inc|Price:5.380|Chg%:+0.150 - TradingKey
Bollard Group LLC Reduces Position in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Aclaris Therapeutics, Inc. Revenue Breakdown – NASDAQ:ACRS - TradingView
Aclaris Therapeutics Inc (ACRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Monashee Investment Management LLC Invests $1.88 Million in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Aclaris Therapeutics (NASDAQ:ACRS) Reaches New 52-Week HighHere's Why - MarketBeat
Piper Sandler Reaffirms Their Buy Rating on Aclaris Therapeutics (ACRS) - The Globe and Mail
Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Vitiligo Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Dermira, Amgen, Pfizer, Dermavant Sciences, Incyte, TWi Biotechnology, Aclaris - Barchart.com
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 2500 Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 2000 Growth Benchmark - marketscreener.com
Aclaris Therapeutics (ACRS) Declines 1.6% as Shares Approach Support at $4.67Ease of Movement - po-news-eg.net
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 3000E Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to sales forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Price to book forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Enterprise value to EBIT forward of Aclaris Therapeutics, Inc. – DUS:8AT - TradingView
Price to earnings forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Price to earnings forward of Aclaris Therapeutics, Inc. – DUS:8AT - TradingView
Enterprise value to EBITDA forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Aclaris Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACRS) - TradingView
ACRS Forecast — Price Target — Prediction for 2027 - TradingView
ACRS Q1 2026 Earnings: Narrows Loss Per Share as Pre-Revenue Biotech Advances PipelineProfit Cycle Analysis - dars.gov.et
We Think Aclaris Therapeutics (NASDAQ:ACRS) Can Afford To Drive Business Growth - Moomoo
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):